tbuckley/cabot-search huggingface dataset:
Prognostic and Predictive Biomarkers in Precursor B-cell Acute Lymphoblastic Leukemia
Authors: Lei Zhang, Sahibu Sultan M. Habeebu, Weijie Li
Journal: Leukemia (2022)

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy characterized by clonal proliferation of abnormal B-cell precursors in the bone marrow. Most of the B-ALL cases are diagnosed in children, although it can present at any age. Thanks to the tremendous advances in our understanding of its biology, identification of more and more prognostic and predictive biomarkers, and application of individualized risk-adjusted treatment, B-ALL has become the most curable malignancy in children, with a long-term survival rate close to 90% in newly diagnosed patients. However, the prognosis of B-ALL remains dismal in adults and children with relapse. Relapsed B-ALL continues to be the leading cause of cancer-related death in children and young adults. Risk stratification is currently based on age, white blood cell count, early therapeutic response, and chromosomal abnormalities such as ploidy and translocations. Recent advances in molecular diagnostic technologies have led to a rapid expansion of the list of molecular biomarkers associated with B-ALL, which show promise to improve the accuracy of risk prediction, and eventually achieve better risk-adapted treatment and clinical outcome. In this chapter, we provide an overview of the prognostic and predictive biomarkers in B-ALL, including some recently identified genomic alterations with significant prognostic impact.
Is it time to rethink the current patient-reported outcome measures?
Authors: Findlay MacAskill, Arun Sahai, Majed Shabbir, Prokar Dasgupta, Paul Cathcart, Amy Sandher, Karen Briggs, Christian Brown, Jonathan Noel, Ben Challacombe, Rick Popert, Raveen Sandher, Claire Taylor, Sachin Malde, Tet Yap
Journal: Nature Reviews Urology (2022)
Environmental Pollutants Are Associated With Irritable Bowel Syndrome in a Commercially Insured Cohort of California Residents
Authors: Philip N. Okafor, Alex Dahlen, Michael Youssef, Adegboyega Olayode, Irene Sonu, Leila Neshatian, Linda Nguyen, Vivek Charu
Journal: Clinical Gastroenterology and Hepatology (2022)
Reply to Liu et al.: “Effects of cognitive behavioral therapy for insomnia (CBT-I) on quality of life: A systematic review and meta-analysis”
Authors: Zainab Alimoradi, Anders Broström, Maurice M. Ohayon, Chung-Ying Lin, Mark D. Griffiths, Susanna Jernelöv, Viktor Kaldo, Amir H. Pakpour
Journal: Sleep Medicine Reviews (2022)
Lung cancer: NHS campaign aims to inflate numbers of early diagnoses
Authors: Alison Shepherd
Journal: BMJ (2022)

<h3>Abstract</h3> Under global warming, advances in spring phenology due to the rising temperature have been widely reported. However, the physiological mechanisms underlying the warming-induced earlier spring phenology remain poorly understood. Here, using multiple long-term and large-scale phenological datasets between 1951 and 2018, we show that warmer temperatures during the previous growing season between May and September led to earlier spring phenology in the Northern Hemisphere. We also found that warming-induced increases in maximum photosynthetic rate in the previous year advanced spring phenology, with an average of 2.50 days °C<sup>-1</sup>. Furthermore, we found a significant decline in the advancing effect of warming during the previous growing season on spring phenology from cold to warm periods over the past decades. Our results suggest that the observed warming-induced earlier spring phenology may be driven by increased photosynthetic carbon assimilation in the previous season, while the slowdown in the advanced spring phenology arise likely from decreased carbon assimilation when warming exceeding the optimal temperatures for photosynthesis. Our study highlights the vital role of photosynthetic carbon assimilation during growing season in spring phenology under global warming.
Dissecting Manual, Based on Cunningham's Anatomy.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poster sessions
Authors: Russell Wiesner, Michael Sorrell, William Wall, Glenn Krinsky, Richard Freeman, V Menon, Patrick Kamath, Andrew Klein, Lydia Petrovic, Hugo Rosen, Robert Gish, Hugo Vargas, Anthony Demetris, Nathan Bass, Bernard Portmann, Michael Lucey, Paul Thuluvath, Stephan Kanzler, Stephen Caldwell, Gregory Ginsberg, Ananya Das, Anthony Kalloo, Michael Narkewicz, Karen Murray, Stephen Harrison, Arie Regev, Michael Charlton, Kris Kowdley, Anna Lok, Jorge Marrero, Bruce Luxon, Bruce Bacon, Steven Herrine, Gregory Gores, Shelly Lu, Guadalupe Garcia-Tsao, Jacquelyn Maher, Arthur Mccullough, Susan Orloff, Sanjeev Gupta, Pierre Clavien, Kim Olthoff, John Lake, Robert Brown, E Heathcote, Christopher Day
Journal: Hepatology (2006)

CME Credits• Discuss the significant role liver biopsy plays in the management of the liver transplant recipient.• Explain the importance of hepatic radiology in the diagnosis and treatment of hepatobiliary disease in the pre-and posttransplant patients.• Summarize the advancements in the diagnosis and treatment of specific liver disease which are common indications for liver transplantation including hepatitis B, hepatitis C, hepatocellular cancer, and primary sclerosing cholangitis.This course will demonstrate the importance of collaborative relationships between hepatic pathologists and hepatic radiologists working in close concert with the liver transplant surgeon and transplant hepatologists to provide expert clinical care to the liver transplant recipient both pre-and posttransplant.
The British Society of Gastroenterology
Authors: S Bown, D Storey, P Swain, J Kirkham, C Northfield, M Atkinson
Journal: Gut (1981)

One hundred and eighteen prosthetic tubes were inserted at fibreoptic endoscopy across oesophagogastric neoplasms.These were followed up for a total of 428 tube months.Food blockage occurred on 24 occasions and this was related to the length of the tube.Thirteen tubes displaced proximally, eight of which had no distal shoulder.Distal displacement oc- curred once, requiring laparotomy and two tubes disappeared without trace.Structural deterioration resulted in disintegration and fragmentation in two tubes, three and eight months after insertion.Using the Instron method, tensile strengths of virgin latex and silicone rubber tubes were measured in vitro after accelerated ageing by intubation in varying concentrations of hydrochloric acid and bile.After incubation in 01 M on August 15, 2023 by guest.
Esophageal Tumors in Sheep: Some Ecological Observations
Authors: Karl H. Schütte
Journal: JNCI Journal of the National Cancer Institute (1968)

The occurrence of esophageal tumors in sheep on a large farm near Cradock, Cape Province, South Africa, is recorded. The tumors were found only during a 10-year period in which lambs were drenched with a mixture of nicotine sulfate and copper sulfate to combat internal parasites. During this time the sheep on a plateau grassland showed an incidence of over 8% of gullet tumor, while those grazing in scrub-covered valley bottoms and on hills did not show this condition. When the drench was changed, there was no further gullet tumor in the flocks. The tumors appear to be environmentally linked in some way. Their exact nature was not determined. Some tentative conclusions regarding the etiology of the tumors are proposed.
Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats
Authors: María Casadevall, Julián Panés, Josep M. Piqué, Norma Marroni, Jaume Bosch, Brendan J. R. Whittle
Journal: Hepatology (1993)

This study investigates the effects of inhibition of nitric oxide synthesis by N G -nitro-L-arginine methyl ester (L-NAME), the inhibition of prostaglandin synthesis with indomethacin and the combined effects on gastric mucosal hyperemia of ketamine-anesthetized rats with portal hypertension induced by partial portal vein ligation. The hydrogen gas-clearance technique was used for measurement of gastric mucosal blood flow. Blood pressure increased with L-NAME administration in a similar manner in portal-hypertensive and sham-operated rats. Low doses of L-NAME (1 and 3 mg/kg, intravenously) caused a significant and dosedependent reduction in gastric mucosal blood flow in portal-hypertensive rats but had no effect on shamoperated animals. With a higher dose of L-NAME (13 mg/kg, intravenously), a significant decrease in gastric mucosal blood flow was observed in both portal-hypertensive and sham-operated rats. Indomethacin pretreatment (5 mg/kg, subcutaneously) caused a significant decrease in basal gastric mucosal blood flow of portal-hypertensive rats but did not modify this parameter in sham-operated animals. In sham-operated rats pretreated with indomethacin, the lower dose of L-NAME (3 mg/kg) did not significantly modify basal gastric mucosal blood flow. Likewise, pretreatment with indomethacin in sham-operated rats did not augment the significant reduction in gastric mucosal blood flow produced by the higher dose of L-NAME. In portal-hypertensive rats the significant dose-dependent reduction in gastric mucosal blood flow induced by L-NAME (3 and 13 mg/kg) was not significantly altered by pretreatment with indomethacin. Portal pressure was higher in portal-hypertensive than in sham-operated rats, and no significant differences were observed in this parameter between portal-hypertensive animals treated with different doses of L-NAME. These results indicate that both nitric oxide and prostaglandins may be involved in the gastric mucosal hyperemia of portal-hypertensive rats. However, no synergistic interactions between these two endogenous vasodilators could be observed in this experimental model. (HEPATOLOGY 1993;18:628-634.)
COUNCIL ON FOODS AND NUTRITION
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Introduction to the Study of the Protozoa With Special Reference to the Parasitic Forms.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prophage-encoded immune evasion factors are critical for Staphylococcus aureus host infection, switching, and adaptation
Authors: Chrispin Chaguza, Joshua T. Smith, Spencer A. Bruce, Robert Gibson, Isabella W. Martin, Cheryl P. Andam
Journal: Cell Genomics (2022)

is a multi-host pathogen that causes infections in animals and humans globally. The specific genetic loci-and the extent to which they drive cross-species switching, transmissibility, and adaptation-are not well understood. Here, we conducted a population genomic study of 437
Hypothalamic astrocytes control systemic glucose metabolism and energy balance
Authors: Daniela Herrera Moro Chao, Matthew K. Kirchner, Cuong Pham, Ewout Foppen, Raphael G.P. Denis, Julien Castel, Chloe Morel, Enrica Montalban, Rim Hassouna, Linh-Chi Bui, Justine Renault, Christine Mouffle, Cristina García-Cáceres, Matthias H. Tschöp, Dongdong Li, Claire Martin, Javier E. Stern, Serge H. Luquet
Journal: Cell Metabolism (2022)
Two independent respiratory chains adapt OXPHOS performance to glycolytic switch
Authors: Erika Fernández-Vizarra, Sandra López-Calcerrada, Ana Sierra-Magro, Rafael Pérez-Pérez, Luke E. Formosa, Daniella H. Hock, María Illescas, Ana Peñas, Michele Brischigliaro, Shujing Ding, Ian M. Fearnley, Charalampos Tzoulis, Robert D.S. Pitceathly, Joaquín Arenas, Miguel A. Martín, David A. Stroud, Massimo Zeviani, Michael T. Ryan, Cristina Ugalde
Journal: Cell Metabolism (2022)
Organ-specific metabolic pathways distinguish prediabetes, type 2 diabetes, and normal tissues
Authors: Klev Diamanti, Marco Cavalli, Maria J. Pereira, Gang Pan, Casimiro Castillejo-López, Chanchal Kumar, Filip Mundt, Jan Komorowski, Atul S. Deshmukh, Matthias Mann, Olle Korsgren, Jan W. Eriksson, Claes Wadelius
Journal: Cell Reports Medicine (2022)

Environmental and genetic factors cause defects in pancreatic islets driving type 2 diabetes (T2D) together with the progression of multi-tissue insulin resistance. Mass spectrometry proteomics on samples from five key metabolic tissues of a cross-sectional cohort of 43 multi-organ donors provides deep coverage of their proteomes. Enrichment analysis of Gene Ontology terms provides a tissue-specific map of altered biological processes across healthy, prediabetes (PD), and T2D subjects. We find widespread alterations in several relevant biological pathways, including increase in hemostasis in pancreatic islets of PD, increase in the complement cascade in liver and pancreatic islets of PD, and elevation in cholesterol biosynthesis in liver of T2D. Our findings point to inflammatory, immune, and vascular alterations in pancreatic islets in PD that are hypotheses to be tested for potential contributions to hormonal perturbations such as impaired insulin and increased glucagon production. This multi-tissue proteomic map suggests tissue-specific metabolic dysregulations in T2D.
SARS-CoV-2 3CL <sup>pro</sup> mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Authors: Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, Andre Volland, Claudia Ascher, Alexander Kurt Hermann Weiss, David Bante, Reuben S. Harris, Stefano Moro, Bernhard Rupp, Luis Martinez-Sobrido, Dorothee von Laer
Journal: Science Translational Medicine (2022)

Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has been licensed for clinical use. To identify mutations that confer resistance to this protease inhibitor, we engineered a chimeric vesicular stomatitis virus (VSV) that expressed a polyprotein composed of the VSV glycoprotein (G), the SARS-CoV-2 3CLpro, and the VSV polymerase (L). Viral replication was thus dependent on the autocatalytic processing of this precursor protein by 3CLpro and release of the functional viral proteins G and L, and replication of this chimeric VSV was effectively inhibited by nirmatrelvir. Using this system, we applied nirmatrelvir to select for resistance mutations. Resistance was confirmed by retesting nirmatrelvir against the selected mutations in additional VSV-based systems, in an independently developed cellular system, in a biochemical assay, and in a recombinant SARS-CoV-2 system. We demonstrate that some mutants are cross-resistant to ensitrelvir and GC376, whereas others are less resistant to these compounds. Furthermore, we found that most of these resistance mutations already existed in SARS-CoV-2 sequences that have been deposited in the NCBI and GISAID databases, indicating that these mutations were present in circulating SARS-CoV-2 strains.
Single-cell dissection of the obesity-exercise axis in adipose-muscle tissues implies a critical role for mesenchymal stem cells
Authors: Jiekun Yang, Maria Vamvini, Pasquale Nigro, Li-Lun Ho, Kyriakitsa Galani, Marcus Alvarez, Yosuke Tanigawa, Ashley Renfro, Nicholas P. Carbone, Markku Laakso, Leandro Z. Agudelo, Päivi Pajukanta, Michael F. Hirshman, Roeland J.W. Middelbeek, Kevin Grove, Laurie J. Goodyear, Manolis Kellis
Journal: Cell Metabolism (2022)

Exercise training is critical for the prevention and treatment of obesity, but its underlying mechanisms remain incompletely understood given the challenge of profiling heterogeneous effects across multiple tissues and cell types. Here, we address this challenge and opposing effects of exercise and high-fat diet (HFD)-induced obesity at single-cell resolution in subcutaneous and visceral white adipose tissue and skeletal muscle in mice with diet and exercise training interventions. We identify a prominent role of mesenchymal stem cells (MSCs) in obesity and exercise-induced tissue adaptation. Among the pathways regulated by exercise and HFD in MSCs across the three tissues, extracellular matrix remodeling and circadian rhythm are the most prominent. Inferred cell-cell interactions implicate within- and multi-tissue crosstalk centered around MSCs. Overall, our work reveals the intricacies and diversity of multi-tissue molecular responses to exercise and obesity and uncovers a previously underappreciated role of MSCs in tissue-specific and multi-tissue beneficial effects of exercise.
Feasibility of time-restricted eating and impacts on cardiometabolic health in 24-h shift workers: The Healthy Heroes randomized control trial
Authors: Emily N.C. Manoogian, Adena Zadourian, Hannah C. Lo, Nikko R. Gutierrez, Azarin Shoghi, Ashley Rosander, Aryana Pazargadi, Cameron K. Ormiston, Xinran Wang, Jialu Sui, Zhaoyi Hou, Jason G. Fleischer, Shahrokh Golshan, Pam R. Taub, Satchidananda Panda
Journal: Cell Metabolism (2022)

Over a quarter of the workforce in industrialized countries does shift work, which increases the risk for cardiometabolic disease. Yet shift workers are often excluded from lifestyle intervention studies to reduce this risk. In a randomized control trial with 137 firefighters who work 24-h shifts (23-59 years old, 9% female), 12 weeks of 10-h time-restricted eating (TRE) was feasible, with TRE participants decreasing their eating window (baseline, mean 14.13 h, 95% CI 13.78-14.47 h; intervention, 11.13 h, 95% CI 10.73-11.54 h, p = 3.29E-17) with no adverse effects, and improved quality of life assessed via SF-36 (ClinicalTrials.gov: NCT03533023). Compared to the standard of care (SOC) arm, TRE significantly decreased VLDL particle size. In participants with elevated cardiometabolic risks at baseline, there were significant reductions in TRE compared to SOC in glycated hemoglobin A1C and diastolic blood pressure. For individuals working a 24-h shift schedule, TRE is feasible and can improve cardiometabolic health, especially for individuals with increased risk. VIDEO ABSTRACT.
Late isocaloric eating increases hunger, decreases energy expenditure, and modifies metabolic pathways in adults with overweight and obesity
Authors: Nina Vujović, Matthew J. Piron, Jingyi Qian, Sarah L. Chellappa, Arlet Nedeltcheva, David Barr, Su Wei Heng, Kayla Kerlin, Suhina Srivastav, Wei Wang, Brent Shoji, Marta Garaulet, Matthew J. Brady, Frank A.J.L. Scheer
Journal: Cell Metabolism (2022)
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
Authors: Cherie-Ann O. Nathan, D. Neil Hayes, Theodore Karrison, Olivier Harismendy, José M. Flores, Tara Moore-Medlin, Everett E. Vokes, J. Silvio Gutkind, Prakash Neupane, Glenn Mills, Zoukaa Sargi, Tanguy Seiwert, Juneko Grilley-Olson, Terry Day, Maura Gillison, James L. Wade, Lawrence Feldman, Gautam Jha, Mark Kozloff, Miriam O'Leary, Francis P. Worden, Ezra E.W. Cohen
Journal: Clinical Cancer Research (2022)

Investigate whether adjuvant everolimus, an mTOR inhibitor, improves progression-free survival (PFS) in advanced-stage head and neck squamous cell carcinoma (HNSCC) and provide outcomes related to correlative biological factors associated with disease control.This was a prospective, randomized, double-blind phase II trial of patients with advanced-stage HNSCC from 13 institutions who were confirmed disease-free post-definitive therapy and enrolled between December 2010 and March 2015. Patients received adjuvant everolimus or placebo daily (10 mg, oral) for a maximum of 1 year. p16 IHC as a surrogate marker for human papillomavirus infection and whole-exome sequencing were performed. Cox proportional hazard models estimated hazard rates. Log-rank tests evaluated differences in survival. The primary endpoint was PFS. Secondary endpoints and objectives included overall survival (OS) and toxicity assessment.52 patients [median (range) age, 58 (37-76) years; 43 men (83%), 9 women (17%)] were randomized to placebo (n = 24) or everolimus (n = 28). PFS favored everolimus, but was not significant [log-rank P = 0.093; HR = 0.44; 95% confidence interval (CI), 0.17-1.17]. There was no difference in OS (P = 0.29; HR = 0.57; 95% CI, 0.20-16.2). Everolimus resulted in significant improvement in PFS for p16-negative patients (n = 31; P = 0.031; HR = 0.26; 95% CI, 0.07-0.97), although subgroup analysis showed no difference for p16-positive patients (n = 21; P = 0.93). Further, PFS was significantly higher in TP53-mutated (TP53mut) patients treated with everolimus compared with placebo (log-rank P = 0.027; HR = 0.24; 95% CI, 0.06-0.95). No treatment difference was seen in patients with TP53 wild-type tumors (P = 0.79).p16-negative and TP53mut patients may benefit from adjuvant treatment with everolimus.